Peregrine Pharmaceuticals reported $77.3M in Current Liabilities for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Agenus AGEN:US $ 163.06M 6.12M
Amgen AMGN:US $ 12886M 702M
AstraZeneca AZN:LN 22740M 146M
Biocryst Pharmaceuticals BCRX:US $ 81.02M 22.7M
Bristol Myers Squibb BMY:US $ 22821M 953M
Celldex Therapeutics CLDX:US $ 14.56M 1.97M
Chemocentryx CCXI:US $ 68.81M 5.79M
Eli Lilly And LLY:US $ 13386M 1666.7M
GlaxoSmithKline GSK:LN 24278M 608M
Immunogen IMGN:US $ 84.12M 16.83M
Intrexon XON:US $ 25.6M 9.04M
Karyopharm Therapeutics KPTI:US $ 66.34M 7.38M
Macrogenics MGNX:US $ 67.1M 7.48M
Mannkind MNKD:US $ 53.49M 5.14M
Merk MRK:US $ 22316M 1556M
Minerva Neurosciences NERV:US $ 3.25M 0.43M
Newlink Genetics NLNK:US $ 5.24M 0.11M
Novartis NOVN:VX SF 29807M 401M
Novavax NVAX:US $ 2261M 129.31M
Peregrine Pharmaceuticals PPHM:US $ 77.3M 7.77M
Repligen RGEN:US $ 424.33M 49.07M
Xencor XNCR:US $ 60.94M 9.8M